0001140361-18-029033.txt : 20180618 0001140361-18-029033.hdr.sgml : 20180618 20180618201152 ACCESSION NUMBER: 0001140361-18-029033 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180614 FILED AS OF DATE: 20180618 DATE AS OF CHANGE: 20180618 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FUCHS HENRY J CENTRAL INDEX KEY: 0001197355 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 18905848 MAIL ADDRESS: STREET 1: C/O BIOMARIN PHARMACEUTICAL INC. STREET 2: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 4 1 doc1.xml FORM 4 X0306 4 2018-06-14 0 0001048477 BIOMARIN PHARMACEUTICAL INC BMRN 0001197355 FUCHS HENRY J C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901 0 1 0 0 President, Worldwide R&D Common Stock 2018-06-14 4 M 0 2000 21.510 A 157167 D Common Stock 2018-06-14 4 S 0 2000 90.00 D 155167 D Common Stock 2018-06-14 4 M 0 3775 26.490 A 158942 D Common Stock 2018-06-14 4 S 0 3775 90.00 D 155167 D Common Stock 2018-06-14 4 M 0 2669 37.46 A 157836 D Common Stock 2018-06-14 4 S 0 2669 90.00 D 155167 D Common Stock 2018-06-14 4 M 0 1875 26.49 A 157042 D Common Stock 2018-06-14 4 S 0 1875 90.00 D 155167 D Common Stock 2018-06-14 4 M 0 20681 37.46 A 175848 D Common Stock 2018-06-14 4 S 0 20681 90.0041 D 155167 D Stock Option (Right to buy Common Stock) 21.510 2018-06-14 4 M 0 2000 0 D 2010-11-12 2020-05-11 Common Stock 2000 0 D Stock Option (Right to buy Common Stock) 26.49 2018-06-14 4 M 0 3775 0 D 2011-11-12 2021-05-11 Common Stock 3775 0 D Stock Option (Right to buy Common Stock) 37.46 2018-06-14 4 M 0 2669 0 D 2012-11-08 2022-05-07 Common Stock 2669 0 D Stock Option (Right to buy Common Stock) 26.49 2018-06-14 4 M 0 1875 0 D 2011-11-12 2021-05-11 Common Stock 1875 0 D Stock Option (Right to buy Common Stock) 37.46 2018-06-14 4 M 0 20681 0 D 2012-11-08 2022-05-07 Common Stock 20681 0 D Trade made pursuant to a 10b5-1 plan executed on May 30, 2018. The price in column 4 is the weighted average price. The price actually received ranged from $90.00 to $90.07. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Reflects the number of options outstanding after the transactions from this specific stock option grant. /s/ Eric Fleekop, Attorney-in-Fact 2018-06-18 EX-24 2 poa_fuchs.htm
POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of G. Eric Davis, Laura Randall Woodhead, and Eric Fleekop, signing singly, the undersigned’s true and lawful attorney-in-fact to:

(1)           execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of BioMarin Pharmaceutical Inc. (the “Company”), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2)           do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3)           take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 7th day of June, 2018.

/s/ Henry J. Fuchs, M.D.
  
Henry J. Fuchs, M.D.